Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer
Condition(s):Lung Neoplasms; Erlotinib; Neoadjuvant TherapyLast Updated:May 30, 2013Completed
Hide Studies Not Open or Pending
Condition(s):Lung Neoplasms; Erlotinib; Neoadjuvant TherapyLast Updated:May 30, 2013Completed
Condition(s):Non-small Cell Lung CancerLast Updated:August 24, 2010Unknown status
Condition(s):Lung CancerLast Updated:June 15, 2022Completed
Condition(s):Lung CancerLast Updated:May 15, 2019Completed
Condition(s):Lung CancerLast Updated:January 17, 2024Completed
Condition(s):NSCLC; Stage IIIA (N2)Last Updated:November 30, 2018Terminated
Condition(s):EGF-R Positive Non-Small Cell Lung CancerLast Updated:November 21, 2018Recruiting
Condition(s):Non-small Cell Lung CancerLast Updated:May 28, 2019Completed
Condition(s):Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung CancerLast Updated:February 5, 2024Active, not recruiting
Condition(s):Non-Small Cell Lung CancerLast Updated:May 22, 2008Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.